Literature DB >> 25025015

A case of chronic myeloid leukemia with features of essential thrombocythemia in peripheral blood and bone marrow.

Young Jae Byun1, Byeong-Bae Park1, Eun Sung Lee1, Kyung Soo Choi1, Dae Sung Lee1.   

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by overproduction of myeloid white blood cells. Philadelphia chromosome is an essential finding for CML diagnosis. Generally, a clinical diagnosis of essential thrombocythemia (ET) can be established from isolated marked thrombocytosis in peripheral blood. However, Philadelphia chromosome-positivity or bcr/abl rearrangement with isolated thrombocytosis should be diagnosed as CML, not ET, according to World Health Organization diagnostic criteria. Therefore, CML should not be excluded before confirming the presence of the Philadelphia chromosome or bcr/abl rearrangement in cases of isolated thrombocytosis in peripheral blood. We report a case of CML with clinical features of ET in a patient successfully treated with imatinib.

Entities:  

Keywords:  Chronic myeloid leukemia; Essential thrombocythemia; Philadelphia chromosome

Year:  2014        PMID： 25025015      PMCID： PMC4090334          DOI： 10.5045/br.2014.49.2.127

Source DB:  PubMed          Journal:  Blood Res        ISSN： 2287-979X


  10 in total

1.  BCR-ABL rearrangement is not detectable in essential thrombocythemia.

Authors:  G Emilia; R Marasca; P Zucchini; P Temperani; M Luppi; G Torelli; F Lanza; C De Angelis; D Gandini; G L Castoldi; D Vallisa; L Cavanna; L del Senno
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

Review 2.  Chronic myeloid leukemia.

Authors:  C L Sawyers
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

Review 3.  Imatinib mesylate--a new oral targeted therapy.

Authors:  David G Savage; Karen H Antman
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

Review 4.  Typical essential thrombocythaemia does not express bcr-abelson fusion transcript.

Authors:  G Damaj; E Delabesse; C Le Bihan; V Asnafi; M Rachid; F Lefrère; I Radford-Weiss; E Macintyre; O Hermine; B Varet
Journal:  Br J Haematol       Date:  2002-03       Impact factor: 6.998

5.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

6.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

7.  Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome.

Authors:  D B Stoll; P Peterson; R Exten; J Laszlo; A V Pisciotta; J T Ellis; P White; K Vaidya; M Bozdech; S Murphy
Journal:  Am J Hematol       Date:  1988-02       Impact factor: 10.047

8.  Essential thrombocythemia with BCR/ABL rearrangement.

Authors:  Y L Kwong; E K Chiu; R H Liang; V Chan; T K Chan
Journal:  Cancer Genet Cytogenet       Date:  1996-07-01

9.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

Review 10.  Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia.

Authors:  Jan Jacques Michiels; Zwi Berneman; Wilfried Schroyens; Jack Kutti; Birgitta Swolin; Börje Ridell; Pagani Fernando; Ulises Zanetto
Journal:  Ann Hematol       Date:  2004-05-26       Impact factor: 3.673
  10 in total
  3 in total

1.  Microfluidic device for expedited tumor growth towards drug evaluation.

Authors:  Christopher George Uhl; Yaling Liu
Journal:  Lab Chip       Date:  2019-04-09       Impact factor: 6.799

Review 2.  Clinical Features and Outcomes of Patients With Chronic Myeloid Leukemia Presenting With Isolated Thrombocytosis: A Systematic Review and a Case From Our Institution.

Authors:  Dawood Findakly; Waqas Arslan
Journal:  Cureus       Date:  2020-06-23

3.  Chronic Myeloid Leukemia: A Case of Extreme Thrombocytosis Causing Syncope and Myocardial Infarction.

Authors:  Rawaa Ebrahem; Brittany Ahmed; Salam Kadhem; Quoc Truong
Journal:  Cureus       Date:  2016-02-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.